Meeting
2020 ASCO Virtual Scientific Program
First in-human study of in vivo imaging of ex vivo labeled CAR T cells with dual PET-MR.
Authors
Ritu Singla
Cell Therapies, Peter MacCallum Cancer Centre, Melbourne, Australia
Ritu Singla , Dominic M Wall , Samuel Anderson , Nicholas Zia , James C Korte , Lucy Kravets , Gerard McKiernan , Jeanne Butler , Amanda Gammilonghi , Jyoti Arora , Ben J Solomon , Rodney J. Hicks , Timothy Cain , Phillip K. Darcy , Carleen Cullinane , Paul J. Neeson , Rajesh Ramanathan , Ravi Shukla , Vipul Bansal , Simon J. Harrison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
HREC/16/PMCC/30
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3557)
DOI
10.1200/JCO.2020.38.15_suppl.3557
Abstract #
3557
Poster Bd #
287
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Selective recognition of over-expressed self-antigens in solid tumors using calibrated CAR-T therapy.
First Author: Farzad Haerizadeh
Poster
2013 ASCO Annual Meeting
Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).
First Author: Susan F. Slovin
Poster
2013 Genitourinary Cancers Symposium
Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).
First Author: Susan F. Slovin
Poster
2024 ASCO Genitourinary Cancers Symposium
Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.
First Author: Kevin Chang